TGTX - TG Therapeutics, Inc.
| Previous Close | 13.40 |
| Open | 13.45 |
| Bid | 12.95 x 3100 |
| Ask | 14.10 x 2900 |
| Day's Range | 13.10 - 13.60 |
| 52 Week Range | 7.25 - 17.35 |
| Volume | 623,196 |
| Avg. Volume | 966,736 |
| Market Cap | 1.044B |
| Beta | 2.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.67 |
- Zacks•5 days ago
Implied Volatility Surging for TG Therapeutics (TGTX) Stock Options
Investors in TG Therapeutics (TGTX) need to pay close attention to the stock based on moves in the options market lately.
- ACCESSWIRE•5 days ago
Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on TRVN sign up now at www.wallstequities.com/registration. On Monday, July 09, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green.
- GlobeNewswire•25 days ago
TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody
TG Therapeutics, Inc. (TGTX) and Novimmune SA, today announced that the companies have entered into an exclusive global agreement to collaborate on the development and commercialization of Novimmune’s novel first-in-class anti-CD47/anti-CD19 bispecific antibody known as TG-1801 (previously NI-1701). TG Therapeutics will make up-front and milestones payments based on early clinical development, and will be responsible for the costs of clinical development of the products through the end of Phase II, after which TG Therapeutics and Novimmune will be jointly responsible for all development and commercialization costs of the product.
- GlobeNewswire•27 days ago
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology
TG Therapeutics, Inc. (TGTX), today announced updated results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS). The data is being presented today at the 4th Congress of the European Academy of Neurology in Lisbon, Portugal, via an oral session titled “MS and related Disorders 2”, at 17:00 CET. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, stated, “We are extremely pleased to see that the preliminary Week 48 data presented today from this Phase 2 trial supports the Week 24 data presented earlier this year at the AAN meeting.
- GlobeNewswire•27 days ago
TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23rd Congress of the European Hematology Association (EHA)
TG Therapeutics, Inc. (TGTX), today announced an oral presentation of clinical data from its ongoing Phase 2 study evaluating umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “We are pleased to present data evaluating umbralisib in patients intolerant to currently approved BTK or PI3K therapies during the EHA annual congress.
- GlobeNewswire•last month
TG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23rd Congress of the European Hematology Association
TG Therapeutics, Inc. (TGTX), today announced the presentation of an integrated analysis of long term safety data of umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, either dosed as a single agent and in combination, in patients with relapsed or refractory lymphoid malignancies, as well as the first preclinical data presentation of TG-1701, the Company’s orally available and covalently-bound BTK inhibitor. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “We are extremely pleased to present updated data from our integrated safety analyses of umbralisib.
- GlobeNewswire•last month
TG Therapeutics, Inc. Announces Oral Presentation of Umbralisib plus Ruxolitinib in Patients with Myelofibrosis at the 23rd Congress of the European Hematology Association
TG Therapeutics, Inc. (TGTX), today announced updated clinical data from its ongoing Phase I study evaluating umbralisib (TGR-1202), the Company’s PI3K delta inhibitor in combination with ruxolitinib, the JAK 1/2 inhibitor, in ruxolitinib experienced patients with myelofibrosis (MF).
- Insider Monkey•last month
This Biotech Investor’s Picks Returned 31% in Q1; Here Are Its New Bets
Peter Kolchinsky is one of the best biotech investors and many of his stock picks generate strong returns. We calculate a fund’s returns by taking into account the long positions in companies with a market cap above $1.0 billion and Kolchinsky’s RA Capital Management was the best performing fund among those in our database in […]
- ACCESSWIRE•last month
TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want a free Stock Review on TGTX sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: TG Therapeutics Inc. (NASDAQ: TGTX), Trevena Inc. (NASDAQ: TRVN), United Therapeutics Corp. (NASDAQ: UTHR), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA).
- Motley Fool•last month
3 Cancer Stocks That Could Soar in the Second Half of 2018
Keep your eyes open for big catalysts that could give these biotech stocks a push in the right direction.
- GlobeNewswire•last month
TG Therapeutics, Inc. to Present at the Jefferies 2018 Global Healthcare Conference
TG Therapeutics, Inc. (TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference, being held at the Grand Hyatt Hotel, in New York City. The presentation is scheduled to take place on Thursday, June 7, 2018 at 10:30am ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
- Motley Fool•last month
ASCO 2018 Sends TG Therapeutics Stock Soaring 10% Today
A presentation at the highly watched conference is sparking investor optimism.
- GlobeNewswire•last month
TG Therapeutics, Inc. Announces Umbralisib Clinical Data Presentation at the 54th Annual Meeting of the American Society of Clinical Oncology
TG Therapeutics, Inc. (TGTX), today announced updated clinical data from its ongoing Phase 2 study evaluating umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “We are extremely pleased with the data presented today during the ASCO annual meeting.
- GlobeNewswire•last month
TG Therapeutics, Inc. Appoints Adam Waldman as Chief Commercial Officer
Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “We are extremely pleased to welcome Adam to the TG Therapeutics team. Adam Waldman stated, “I am thrilled to be joining TG Therapeutics with the opportunity to build a world class commercial team and to launch multiple new products over the next few years.
- GlobeNewswire•last month
TG Therapeutics, Inc. Recaps Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association
NEW YORK, June 01, 2018-- TG Therapeutics, Inc., today recapped the schedule of data presentations at the upcoming 54 th Annual Meeting of the American Society of Clinical Oncology, to be held from June ...
- GlobeNewswire•2 months ago
TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association
NEW YORK, May 17, 2018-- TG Therapeutics, Inc., today announced that abstracts featuring umbralisib, the Company's once-daily PI3K delta inhibitor, and TG-1701, the Company’ s orally available BTK inhibitor, ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of TGTX earnings conference call or presentation 8-May-18 12:30pm GMT
Q1 2018 TG Therapeutics Inc Earnings Call
- Associated Press•2 months ago
TG Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 59 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•2 months ago
TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2018 Financial Results
NEW YORK, May 08, 2018-- TG Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2018 and recent company developments.. Michael S. Weiss, the Company's Executive ...
- GlobeNewswire•2 months ago
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2018 Financial Results and Business Update
TG Therapeutics, Inc. (TGTX), today announced that a conference call will be held on Tuesday, May 8, 2018 at 8:30am ET to discuss results for the first quarter of 2018 and provide a business outlook for the remainder of the year. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will host the call. An audio recording of the conference call will also be available for replay on the Company’s website, for a period of 30 days after the call. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases.
- GlobeNewswire•2 months ago
Recent Analysis Shows FTD Companies, TG Therapeutics, National HealthCare, Lennox International, PRA Group, and Unit Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•3 months ago
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting
NEW YORK, April 24, 2018-- TG Therapeutics, Inc., today announced updated results from the Phase 2 multicenter trial of ublituximab, the Company’ s novel glycoengineered anti-CD20 monoclonal antibody, ...
- Motley Fool•3 months ago
3 Biotech Stocks With Major Catalysts Incoming
Highly anticipated events expected in the weeks ahead could set these three biotechs up for long-term success.
- GlobeNewswire•3 months ago
TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting
TG Therapeutics, Inc. (TGTX), today announced preclinical data for TG-1601, the Company’s novel BET inhibitor at the American Association for Cancer Research (AACR) annual meeting, taking place this week in Chicago, Illinois, at McCormick Place North/South. The Company’s poster is available for viewing today from 8:00am to 12:00pm CT, during the Experimental and Molecular Therapeutics/ Canonical Targets 2 Session in Exhibit Hall A.
